Parallel and cross-resistances of clinical yeast isolates determined by susceptibility pattern analysis

Abstract

For calculated initial antifungal therapy, knowledge on parallel and cross-resistances are vitally important particularly in the case of multiresistant isolates. Based on a strain collection of 1,062 yeast isolates from a German/Austrian multicentre study, susceptibility pattern analysis (SPA) was used to determine the proportion of parallel and cross-resistances to eight antifungal agents (AFAs) encompassing flucytosine, amphotericin B, azoles (fluconazole, voriconazole and posaconazole) and echinocandins (caspofungin, micafungin and anidulafungin). A total of 414 (39.0%) isolates were resistant for one or more of the AFAs. Resistance to one AFA was shown for 18.1% of all isolates. For 222 isolates (20.9%), resistance to two to seven AFAs was noted (7.7%; 7.7%; 3.6%; 1.0%; 0.7% and 0.2% to 2, 3, 4, 5, 6 and 7 antifungal compounds, respectively). Partial parallel resistances within the azole and echinocandin classes, respectively, were found for 81 (7.6%) and 70 (6.6%) isolates. Complete parallel resistances for azoles, echinocandins and combined for both classes were exhibited by 93 (8.8%), 18 (1.7%) and 6 (0.6%) isolates, respectively. Isolates displaying cross-resistances between azoles and echinocandins were infrequently found. Highly resistant isolates (resistance to ≥6 AFAs) were almost exclusively represented by Candida albicans. Highly standardized testing of AFAs in parallel and from the same inocula followed by SPA allows detailed insights in the prevalence and distribution of susceptibility patterns of microbial isolates.

Keywords: Candida, antifungals, flucytosine, amphotericin B, fluconazole, voriconazole, posaconazole, caspofungin, micafungin, anidulafungin, susceptibility testing, susceptibility pattern analysis, parallel resistance, cross-resistance

Background

Treatment options for invasive fungal infections are restricted by a very limited number of applicable antifungal agent (AFA) classes. Due to extensive worldwide use of fluconazole in the past decades, azole resistance has been significantly emerged, often associated with clinical failure [1], [2], [3], [4]. Also for the other AFA classes, resistances with substantial consequences for treatment and patient outcome have been increasingly reported [5], [6], [7], [8], [9], [10].

There is mounting evidence that the serious phenomenon of multi-resistance has reached also infections due to fungal pathogens. While reports on testing susceptibilities of yeast isolates to individual antifungals are available for many parts of the world [11], [12], [13], [14], systematic data on parallel and cross-resistances of Candida and other yeast isolates towards azoles, echinocandins, polyenes and flucytosine are still rare [15]. Of note, the terms “parallel resistances” and “cross-resistances” are often undifferentiated and/or varying used today. Here, parallel resistance (PR) was defined as resistance of a given isolate to all antifungal agents within an antifungal class and cross-resistance (CR) as resistance of a given isolate to antifungal agents belonging to different classes of antifungals.

Previously, we have analyzed the AFA susceptibilities of 1,062 yeast isolates recovered from clinical specimens within a collaborative study including 17 participating medical centres mainly by standard susceptibility testing analyses [12]. Here, susceptibility pattern (SP) analysis (SPA) was applied allowing a highly standardized analysis and true comparison of antifungal susceptibilities based on determined individual SP of each single isolate [16]. Based on this, we determined the proportion of parallel, cross- and multi-resistances for the clinically most prevalent Candida species, but also for rare yeast species
Table 1: Percentages of yeast isolates (n=1,062) showing complete parallel resistance within azoles and echinocandins and their cross resistance patterns towards FCY and AMB

| Yeast species (n, number of isolates and %, percentage of total) | Complete parallel resistance (RRRR)\(^1\) within AFA class | Cross resistance (RRRR)\(^2\) between |
|---------------------------------------------------------------|-------------------------------------------------|---------------------------------|
|                                                               | Azoles (FLC-VOR-POS)\(^3\) Echinocandins (CAS-MCA-ANI)\(^3\) | Flucytosine (FCY-FLC-VOR-POS)\(^3\) Amphotericin B (AMB-FLC-VOR-POS)\(^3\) Flucytosine (FCY-CAS-MCA-ANI)\(^3\) Amphotericin B (AMB-CAS-MCA-ANI)\(^3\) |
| C. albicans (n=573; 54.0%) | 6.1 | 1.8 | 0.5 | 1.8 | 0.0 | 0.0 | 0.4 |
| C. dubliniensis (n=21; 2.0%) | 0.0 | 23.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| C. famata (n=2; 0.2%) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| C. glabrata (n=234; 22.0%) | 14.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| C. guilliermondii (n=8; 0.8%) | 12.5 | 0.0 | 0.0 | 0.0 | 12.5 | 0.0 | 0.0 |
| C. kafyr (n=10; 0.9%) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| C. krusei (n=46; 4.3%) | 23.7 | 0.0 | 0.0 | 0.0 | 15.2 | 6.5 | 0.0 |
| C. lipolytica (n=5; 0.5%) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| C. lusitaniae (n=13; 1.2%) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| C. melibiosica (n=2; 0.2%) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| C. novegensis (n=2; 0.2%) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| C. parapsilosis (n=64; 6.0%) | 3.1 | 0.0 | 0.0 | 0.0 | 3.1 | 1.6 | 0.0 |
| C. pelliculosa (n=2; 0.2%) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| C. rugosa (n=1; 0.1%) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| C. sake (n=2; 0.2%) | 0.0 | 50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 50.0 |
| C. tropicalis (n=61; 5.7%) | 14.8 | 1.6 | 0.0 | 9.6 | 18.8 | 3.3 | 0.0 |
| S. cerevisiae (n=13; 1.2%) | 15.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| G. capitatum (n=1; 0.1%) | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| G. candidum (n=1; 0.1%) | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 100.0 |
| K. ohmeri (n=1; 0.1%) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total number (percentage) | 93 (8.8) | 18 (1.7) | 18 (1.7) | 23 (2.2) | 1 (0.1) | 4 (0.4) |

\(^1\) Number of isolates for a given species and for all species, respectively, was applied as 100% for species-specific and overall SPA.

\(^2\) SP type according to S-I-R categorization; RRRR, resistance pattern characterized as resistance to three antifungals analyzed; RRRR, resistance pattern characterized as resistance to four antifungals analyzed.

\(^3\) SP basis of the AFA's analyzed.

of interest, isolate- and species-specifically stratified for azoles, echinocandins, flucytosine and amphotericin B.

### Methods

#### Yeast isolates

A total of 1,062 clinical yeast isolates (species distribution, see Table 1) were recovered from clinical relevant routine samples of hospitalized patients and tested for susceptibility within a German/Austrian collaborative study comprising 17 study centres [12]. Details regarding species-specific resistance profiles and AFA-related resistance prevalences have been previously reported [12]. Briefly, 184 (17.3%) specimens were recovered from blood and other normally sterile sites and 878 (82.7%) specimens comprised those from lower respiratory tract (n=299; 34.1%), mouth and throat (n=126; 14.4%), urinary tract (n=166; 18.9%), female genital tract (n=35; 4.0%), gastrointestinal tract (n=61; 6.9%) and other sites (n=191; 21.7%).

### AFA and susceptibility testing

Susceptibility testing was performed as previously published according to DIN (Deutsches Institut für Normung e.V., i.e. the German Institute for Standardization) [12]. Briefly, antifungal agents were tested in parallel in yeast sensitivity test (YST) as log₂-dilution-rows in ready-to-use microdilution trays manufactured by Merlin GmbH (Bornheim-Hersel, Germany) comprising the following range of antifungal concentrations (in μg·L⁻¹): amphotericin B (AMB), 0.008–8.0; flucytosine (FCY), 0.31–32.0; fluconazole (FLC), 0.063–64.0; posaconazole (POS), voriconazole (VOR), anidulafungin (ANI), caspofungin (CAS), and micafungin (MCA), 0.008–8.0. YST medium, which corresponds to the modified HR medium according to DIN 58940-8415 [17], was manufactured by Sifin GmbH (Berlin, Germany). Endpoint reading was performed at 24 h and the MICs were controlled after 48 h incubation at 35±37°C. Minimal inhibitory concentrations (MICs) were determined according to German DIN standards, i.e. the assumed endpoint was the lowest concentration which shows agitation a significant less turbidity than those of 80%-inhibitions control by visual inspection [18], [19].
Statistical analysis was performed with SAS® software (SAS Institute, Cary, NC, USA). The antilog of the calculations was displayed as MICs from calculated results. Differences were assessed by using Chi squared test; P values lower than 0.05 were considered statistically significant.

MICs and MIC interpretive criteria

Details of the in vitro susceptibilities of yeast isolates collected within the multicenter study towards eight antifungal agents have been reported before [12]. Briefly, all drug classes demonstrated multi-modal, at least bimodal MIC distributions. The geometric means of MICs for FLC, POS, VOR, ANI, CAS, MCA, AMB, and FCY for Candida albicans strains (n=573; mg l⁻¹) were 0.6, 0.5, 2.0, 0.1, 0.1, 0.03, 0.1 and 0.03 and for non-C. albicans strains (n=473; mg l⁻¹) 0.8, 0.9, 8.2, 1.3, 0.4, 0.4, 0.2 and 0.04, respectively. MIC categorisation was performed as published by applying interpretative criteria for AMB as published by EUCAST [20] and for FLC as published by DIN [17]. For POS, ANI, CAS, and MCA interpretative criteria published by Pfaffer et al. were used [21], [22]. CLSI criteria were applied for FCY and VOR [23]. Interpretative criteria for susceptible (S) and resistant (R) were: AMB: S≤1.0, R>1.0; FCY, FLC: S≤4.0, R>16.0; POS, VOR: S≤1.0, R>2; and ANI, CAS MCA: S≤2, R>2.0. If appropriate, the values in between were used as intermediate (I). Species-specific breakpoints were not applied. SPs representing sequences of interpretative categories (S, I or R) in a prefixed order of the test results were determined by SPA as described, here in an adaptation for fungal microorganisms [16]. An SP as applied here contains the number of members of antifungal class and the S-I-R categorization (e.g. for a given isolate with completeazole resistance to FLC, POS and VOR: 3R=R-R-R or for an isolate tested susceptible to all eight AFAs included: 8S=S-S-S-S-S-S-S-S).

Resistance definitions

Definitions were applied according to DIN 58940-1 and as published elsewhere [12], [17]. Briefly, multiple resistance (MR) was defined in this study, when two or more antifungal agents independently of any substance class were tested resistant in the same isolate, i.e. representing a random susceptibility pattern. Parallel resistance (PR) was defined as resistance of a given isolate to all (complete PR) or more than one, but not all (partial PR) AFAs within a class of antifungals. Cross-resistance (CR) was defined as resistance of a given isolate to two or more AFAs belonging to different classes of antifungals.

Results

A total of 1,062 clinical yeast isolates (C. albicans, n=573; 54.0%; non-albicans Candida spp., n=473; 44.5%; other yeasts, n=16; 1.5%; further details in Table 1) were enrolled for SPA evaluating their parallel and cross-resistance patterns. Unless otherwise stated, all results given in the text and the tables are based on the application of YST medium and endpoint reading after 48 h. For FCY, FLC, VOR and POS, a threefold categorization (S, I and R) was used and a twofold categorization (S and R) was applied for AMB, CAS, MCA and ANI. Thus, the individual SP of a given isolate represents one SP out of a variety of 1,296 theoretically possible SPs. However, only a limited amount of SPs were found, nevertheless, demonstrating numerous parallel and/or cross-resistant strains. Consequently, only a selection of relevant data restricted (i) to clinically most prevalent Candida species or (ii) to rare yeast species with noticeable SPs has been included in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6 and Table 7. Overall, 62 SPs and 117 SPs were found after 24 h and after 48 h incubation using YST medium. In contrast, applying RPMI medium, the amount of SPs gained after 24 h (n=54) as well as after 48 h (n=86) incubation were less than applying YST medium. However, only the medium-caused difference of SP numbers observed after 48 h reached significance (p<0.05) (data not shown).

Standard susceptibility testing analysis neglecting the individual patterns of susceptibility was compared with SPAs considering isolate-specifically resistances within AFA classes and in between different AFA classes (Table 2), thus, allowing inferences to all naturally occurring SPs in detail. Similar analyses are given for echinocandins and, where appropriate, for FCY and AMB (Table 2). Considering isolates exhibiting exclusive resistance to only one of the AFAs tested, but otherwise tested susceptible (1R7S SP), 93 isolates were found to meet this condition. Including also those isolates otherwise tested susceptible or intermediate (1R7S/I SP), this condition was fulfilled by 192 isolates. While 113 (10.6%) isolates were found to be VOR-resistant by standard analysis, SPA demonstrated that none of these isolates showed exclusive VOR resistance (1R SP) analyzing those isolates tested resistant towards the three azoles included. In contrast, 21 (2.0%) and 23 (2.2%) isolates, respectively, exhibited sole resistance towards FLC and POS, but were tested susceptible towards the otherazole agents (Table 2). Considering all AFAs tested, only five (0.5%) isolates were characterized by exclusive resistance to VOR (Table 2).
Table 2: Standard analysis and SPA of susceptibility testing of yeast isolates (n=1,062)

| Analysis | FCY | AMB | MCA | CAS | ANI |
|----------|-----|-----|-----|-----|-----|
| Number (%) and percentage (%) of isolates resistant to antifungal agents | n | % | n | % | n | % | n | % | n | % |
| FCY | 89 | 8.4 | 120 | 11.3 | 173 | 16.3 | 113 | 10.6 | 230 | 21.7 |
| AMB | - | - | - | - | - | - | - | - | - | - |
| MCA | - | - | - | - | - | - | - | - | - | - |
| CAS | - | - | - | - | - | - | - | - | - | - |
| ANI | - | - | - | - | - | - | - | - | - | - |

Overall, this strain collection comprised 519 (48.9%) yeast isolates tested susceptible to all AFAs included. Regarding azoles and echinocandins, respectively, entire susceptibility were noted for 619 isolates (58.3%) and 974 isolates (91.7%). For the most prevalent species, this 3S SP varied for azoles and echinocandins, respectively, as follows: *C. albicans*, 77.5% and 91.8%; *Candida glabrata*, 23.5% and 97.9%; *Candida krusei*, 4.3% and 100%; *Candida parapsilosis*, 67.2% and 73.4% and *Candida tropicalis*, 45.9% and 96.7%.

Partial parallel resistances (SPs: RSS, RRS, SSR, SRR; unconsidering further SPs containing ‘I’ categorization) within the azole and echinocandin classes, respectively, were found for 81 (7.6%) and 70 (6.6%) isolates.

The proportion of complete parallel resistance to all azoles (3R) was 8.8%, while it was 1.7% to all echinocandins (Table 1, Table 3, Table 4). A complete resistance towards all azoles combined with cross-resistance either to FCY or AMB occurred in 1.7% or 2.2% of the isolates.

For echinocandins, this 3R SP together with cross-resistance to FCY and AMB, respectively, was 0.1% and 0.4% (Table 1). The percentage of complete parallel resistance varied species-specifically. Of particular interest, complete parallel echinocandin resistance was observed for 23.8% of all *Candida dubliniensis* isolates (Table 1). A respective echinocandin 3R SP was also documented for *Candida sake* (50%) and both *Geotrichum* species included, however, here, a very limited number of isolates enrolled should be taken in consideration. In contrast, *C. albicans* and *C. tropicalis* exhibited this 3R-SP to less than 2% of the isolates. However, within theazole class, 3.1%, 6.1%, 12.5%, 14.1%, 14.8%, 15.4%, 23.7 and 50.0% of the *C. parapsilosis*, *C. albicans*, *Candida guilliermondii* (only n=8), *C. glabrata*, *C. tropicalis*, *Saccharomyces cerevisiae*, *C. krusei* and *Candida melibiosica* (only n=2) isolates, respectively, showed a complete parallel resistance. Of interest, 1.8% of the *C. albicans* isolates showing complete parallel azole resistance exhibited also AMB resistance, while only 0.4% of complete echinocandin-resistant isolates of this species were tested also AMB-resistant. Other cross-resistance patterns towards AMB and FCY for complete azole- and echinocandin-resistant isolates, respectively, are given in Table 1.

A more detailed overview of cross-resistances for those yeasts exhibiting a complete parallel resistance pattern to all azoles (3R; 8.8%) and echinocandins (3R; 1.7%), respectively, is given in Table 3 and Table 4. Overall, 19.4 and 24.7% of completeazole-resistant yeast isolates were tested resistant also towards FCY and AMB, respectively. Regarding echinocandins, 7.5%, 12.9% and 14.0% of these isolates showed resistance to MCA, CAS and ANI, respectively. Of interest, while all full azole-resistant *C. glabrata* and *C. krusei* isolates were still susceptible towards all echinocandins, 31.4%, 28.6% and 20.0% of full azole-resistant *C. albicans* isolates showed cross resistance to CAS, ANI and MCA (Table 3).
A complete parallel resistance to echinocandins was observed for only 18 yeast isolates. Of these, 16/1046 (1.5%) were represented by species of the *Candida* genus. Also both *Geotrichum* isolates included exhibited this SP (Table 4). Overall, 5.6% and 22.2% of complete echinocandin-resistant yeast isolates were tested resistant also towards FCY and AMB, respectively. Noteworthy, 33.3%, 38.9% and 44.4% of these isolates were also categorized as resistant to VOR, FLC and POS, respectively. For complete echinocandin-resistant *C. albicans* isolates (n=10/57; 1.7%), 60% were tested resistant also towards each of the azoles included. All *C. dubliniensis* isolates of this category (n=5) were susceptible to VOR, while one isolate demonstrated partial parallel resistance to FLC and POS (Table 4).

SPA results for rare yeast species, defined in this study as *Candida* and non-*Candida* yeast species comprising equal or less than five isolates, are given in Table 5. AMB-resistant isolates (each one isolate) were found for *Candida lipolytica*, *C. melibiosica*, *C. sake* and *Geotrichum candidum*. The *Kodamaea ohmeri* isolate was tested susceptible to all AFAs with the exception of FLC (tested intermediate).

### Table 3: Proportion of cross resistances of isolates with complete parallel resistance within theazole class

| Species with isolates (number of isolates according to resolution) | Percentages (%) of cross resistance of isolates with complete parallel resistance to azoles |
|---------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| S | R | S | R | S | R | S | R | S | R |
|---|---|---|---|---|---|---|---|---|---|
| Total of yeast isolates (n=93) | 78.5 | 19.4 | 75.3 | 24.7 | 87.1 | 12.9 | 92.5 | 7.5 | 86.0 | 14.0 |
| (i) *Candida* spp. (n=91) | 78.0 | 19.8 | 74.3 | 25.3 | 86.8 | 13.2 | 92.3 | 7.7 | 85.7 | 14.3 |
| *C. albicans* (n=35) | 88.6 | 8.6 | 71.4 | 28.6 | 68.6 | 31.4 | 80.0 | 20.0 | 71.4 | 28.6 |
| *C. glabrata* (n=33) | 100.0 | 0.0 | 81.8 | 18.2 | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 |
| *C. guilliermondii* (n=1) | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 |
| *C. krusei* (n=10) | 20.0 | 70.0 | 70.0 | 30.0 | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 |
| *C. melibiosica* (n=1) | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 |
| *C. parapsilosis* (n=2) | 0.0 | 100.0 | 50.0 | 50.0 | 100.0 | 0.0 | 100.0 | 0.0 | 50.0 | 50.0 |
| *C. tropicalis* (n=9) | 33.3 | 66.7 | 77.8 | 22.2 | 100.0 | 0.0 | 100.0 | 0.0 | 88.9 | 11.1 |
| (ii) non-*Candida* yeasts (n=2) | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 |
| *S. cerevisiae* (n=2) | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 |

1. Representing 100% in this calculation.
2. Resistance to all azoles tested (i.e. 3R pattern regarding FCL, VOR and POS), S, susceptible, R, resistant.
3. Comprising 8.8% of all yeast isolates (n=1,062) tested.
4. Comprising 8.7% of all isolates (n=1,064) of the *Candida* genus.
5. In addition, one *C. albicans* isolate (2.9%) and one *C. krusei* isolate (10%) were categorized as intermediate.

### Table 4: Proportion of cross resistances of isolates with complete parallel resistance within the echinocandin class

| Species with isolates (number of isolates according to resolution) | Percentages (%) of cross resistance of isolates with complete echinocandin resistance to echinocandins |
|---------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| S | R | S | R | S | R | S | R | S | R |
|---|---|---|---|---|---|---|---|---|---|
| Total of yeast isolates (n=18) | 94.4 | 5.6 | 77.8 | 22.2 | 55.6 | 43.8 | 66.7 | 33.3 | 50.0 | 44.4 |
| (i) *Candida* spp. (n=16) | 93.8 | 6.3 | 81.2 | 18.8 | 56.3 | 43.8 | 62.5 | 37.5 | 56.3 | 43.8 |
| *C. albicans* (n=10) | 100.0 | 0.0 | 80.0 | 20.0 | 40.0 | 60.0 | 40.0 | 60.0 | 40.0 | 60.0 |
| *C. dubliniensis* (n=5) | 100.0 | 0.0 | 100.0 | 0.0 | 80.0 | 20.0 | 100.0 | 0.0 | 80.0 | 20.0 |
| *C. sake* (n=1) | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 |
| (ii) non-*Candida* yeasts (n=2) | 100.0 | 0.0 | 50.0 | 50.0 | 50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| *G. capitatum* (n=1) | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| *G. candidum* (n=1) | 100.0 | 0.0 | 100.0 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |

1. Representing 100% in this calculation.
2. Resistance to all echinocandins tested (i.e. 3R pattern regarding CAS, MCA and ANI), S, susceptible, R, resistant.
3. Comprising 1.7% of all yeast isolates (n=1,002) tested.
4. Comprising 1.6% of all isolates (n=1,046) of the *Candida* genus.
5. The *Geotrichum candidum* isolate was categorized as FLC and POS intermediate; result was not included into the calculation of total of yeast isolates.
Table 5: Detailed results of SPA for rare yeast species

| Number (n) and percentage (%) of isolates | Isolate | S-I-R categorization |
|------------------------------------------|---------|----------------------|
|                                         |         | FCY  | AMB  | FLC  | VOR  | POS  | CAS  | MCA  | ANF  |
| Total of rare *Candida* spp. (n=16; 5.7%) |         |      |      |      |      |      |      |      |      |
| *C. famata* (n=2; 0.2%)                 | 2382    | S    | S    | S    | S    | S    | S    | S    | S    |
|                                         | BK7384  | R    | S    | I    | S    | S    | S    | S    | S    |
| *C. lipolytica* (n=5; 0.5%)             | 900376  | S    | R    | I    | S    | I    | S    | S    | S    |
|                                         | 900381  | R    | S    | S    | S    | S    | S    | S    | S    |
|                                         | 900407  | S    | S    | I    | S    | S    | S    | S    | S    |
|                                         | 900430  | S    | S    | S    | S    | S    | S    | S    | S    |
|                                         | 900431  | S    | S    | S    | S    | S    | S    | S    | S    |
| *C. melibiosica* (n=2; 0.2%)            | VA13313 | S    | S    | R    | R    | R    | S    | S    | S    |
|                                         | VA13313 II | S | R | I | S | S | S | S | S |
| *C. norvegensis* (n=2; 0.2%)            | AN 9422 | I    | S    | R    | I    | I    | S    | S    | S    |
|                                         | VA20978 | S    | S    | I    | S    | S    | S    | S    | S    |
| *C. pelliculosa* (n=2; 0.2%)            | 46 M    | S    | S    | S    | S    | S    | S    | S    | S    |
|                                         | 5 M     | S    | S    | I    | S    | R    | S    | S    | S    |
| *C. rugosa* (n=1; 0.1%)                 | MY 584  | S    | S    | I    | S    | S    | S    | S    | S    |
| *C. sake* (n=2; 0.2%)                   | VA14514 | R    | R    | S    | S    | S    | R    | R    | R    |
|                                         | VA14687 | S    | S    | S    | S    | S    | R    | S    | R    |
| Total of non-*Candida* yeasts (n=3; 0.3%)|         |      |      |      |      |      |      |      |      |
| *G. candidum* (n=1; 0.1%)               | 17 M    | S    | R    | I    | S    | I    | R    | R    | R    |
| *G. capitatum* (n=1; 0.1%)              | 5 W     | S    | S    | S    | R    | R    | R    | R    | R    |
| *K. ohmeri* (n=1; 0.1%)                 | 145910  | S    | S    | I    | S    | S    | S    | S    | S    |

1 Tested in parallel to all eight AFAs tested with the same inoculum.

Overall, complete susceptible SPs to all AFAs tested (8S-SP) were shown for 519/1062 isolates (48.9%) whereas 414 (39.0%) isolates were characterized by resistance to at least one of the AFAs included (≥1R) (Figure 1). The remaining 129 isolates (12.1%) without resistances demonstrated in one or more cases intermediate susceptibilities distributed to seven different SPs. Comparing the proportion of a species within the total amount of study isolates versus its proportion within those isolates exhibiting a complete susceptible phenotype (8S SP), *C. albicans* isolates showed significantly higher proportions compared to other yeast species. This indicates that *C. albicans* isolates are more susceptible to the AFAs tested compared to other species.
Table 6: Candida isolates showing multi-resistant AFA patterns

| SP indicating multi-resistance | Frequency | SP of antifungal agents | Azoles | Echinocandins |
|-------------------------------|-----------|-------------------------|--------|---------------|
|                               | Number (n) | Percentage (%) | FCY    | AMB       | FLC | VOR | POS | CAS | MCA | ANI |
| 7R SP                         |            |                |        |           |     |     |     |     |     |     |
| AM+FL+VO+PO+CA+MC+AN          | 2          | 0.2            | S      | R         | R   | R   | R   | R   |     |     |
| (C. albicans, n=2)            |            |                |        |           |     |     |     |     |     |     |
| 6R SP                         |            |                |        |           |     |     |     |     |     |     |
| FL+VO+PO+CA+MC+AN             | 4          | 0.4            | S      | S         | R   | R   | R   | R   | R   | R   |
| (C. albicans, n=4)            |            |                |        |           |     |     |     |     |     |     |
| AM+FL+VO+PO+CA+AN             | 1          | 0.1            | S      | R         | R   | R   | R   | R   | S   | R   |
| (C. guilliermondii, n=1)      |            |                |        |           |     |     |     |     |     |     |
| FY+AM+FL+VO+PO+CA             | 1          | 0.1            | R      | R         | R   | R   | R   | R   | R   | S   |
| (C. albicans, n=1)            |            |                |        |           |     |     |     |     |     |     |
| FY+AM+FL+VO+PO+AN             | 1          | 0.1            | R      | R         | R   | R   | R   | S   | S   | R   |
| (C. albicans, n=1)            |            |                |        |           |     |     |     |     |     |     |
| 5 R SP                        |            |                |        |           |     |     |     |     |     |     |
| FY+AM+FL+VO+PO                | 5          | 0.5            | R      | R         | R   | R   | R   | S   | S   | S   |
| (C. krusei, n=3; C. parapsilosis and C. tropicalis, each n=1) | | | | | | | | | | |
| FY+AM+CA+MC+AN                | 1          | 0.1            | R      | R         | S   | S   | S   | R   | R   | R   |
| (C. sake, n=1)                |            |                |        |           |     |     |     |     |     |     |
| AM+FL+VO+PO+CA                | 1          | 0.1            | S      | R         | R   | R   | R   | R   | R   | S   |
| (C. albicans, n=1)            |            |                |        |           |     |     |     |     |     |     |
| FL+PO+CA+MC+AN                | 1          | 0.1            | S      | S         | R   | S   | R   | R   | R   | R   |
| (C. dubliniensis, n=1)        |            |                |        |           |     |     |     |     |     |     |
| FL+VO+PO+CA+AN                | 1          | 0.1            | S      | S         | R   | R   | R   | R   | S   | R   |
| (C. albicans, n=1)            |            |                |        |           |     |     |     |     |     |     |
| FY+FL+VO+PO+AN                | 2          | 0.2            | R      | S         | R   | R   | R   | S   | S   | R   |
| (C. albicans and C. parapsilosis, each n=1) | | | | | | | | | | |

1 Multi-resistance defined as resistance towards ≥1 AFA of ≥2 AFA classes; here considering only those isolates exhibiting resistances to ≥5 AFA ≥5R), complete parallel resistance within a AFA class in bold.
2 Tested in parallel to all eight AFA tested with the same inoculum in YST medium and applying 48 h endpoint reading; S susceptible; R resistant.
3 Percentage of all yeast isolates (n=1,062) tested.

an 8S SP (54.0% vs. 75.9% 8S-SP; P<0.01), whereas respective isolates of C. glabrata (22.0% vs. 9.6% 8S-SP; P<0.01), C. krusei (4.3% vs. 0.2%; P<0.01) and C. tropicalis (5.7% vs. 2.5%; P<0.01) displayed significantly less this phenotype.

For 122 (11.5%) of total isolates of the 129 intermediate-tested isolates comprising those without any result categorized as resistant, intermediateazole susceptibility was found as follows: FLC, n=43; POS, n=54; FLC and POS, n=20; FCY and FLC, n=3; FCY and POS, n=1; FCY, FLC and POS, n=1. Intermediate FCY susceptibility was noted for C. albicans (n=5) and Candida kefyr (n=2).

Overall, 222 (20.9%) isolates contained 81 SPs with more than one “R” within the pattern. No isolate was found to be resistant to all eight AFA tested at 24 h and 48 h endpoint reading, respectively. Resistance limited to a single AFA was found in 192 (18.1%) isolates. In 222 isolates (20.9%), resistance patterns to 2–7 AFAs (2-7R) were noted. The distribution of isolates exhibiting resistance to ≥2 AFA was as follows: 2R, n=82 (7.7%); 3R, n=82 (7.7%); 4R, n=82 (3.6%); 5R, n=11 (1.0%); 6R, n=7 (0.7%), and 7R, n=2 (0.2%). SPs with ≥5R reflecting pronounced multi-resistance are given in Table 6 and Figure 1. Of 140 isolates (13.2%) characterized by a 3–7 fold AFA resistance, 97 (9.1%) possessed a complete parallel resistance consisting of 79 (7.4%), 12 (1.1%) and 6 (0.6) isolates showing this SP against all azoles, echinocandins and both AFA classes, respectively. Of note, highly resistant isolates exhibiting 7R- and 6R-patterns were almost exclusively represented by C. albicans with one exception by C. guilliermondii. The two 7R C. albicans strains were still susceptible to flucytosine (Table 6).

The proportion of still susceptible AFA in relation to AFA-stratified resistances has been calculated in Table 7 for the clinically most relevant Candida species. As shown in Table 7, FLC-resistant C. albicans isolates (n=46) displayed susceptibility to one of the echinocandins in more than 76% (CAS, 76.1%; ANI, 78.3% and MCA, 84.8%), but only 13.0% of these FLC-resistant isolates were also susceptible to VOR. Noteworthy, for C. glabrata, this analysis demonstrated that almost all FLC- (n=55), VOR- (n=35) and POS- (n=104) resistant isolates were tested susceptible to all echinocandins with the exception of two CAS-resistant isolates.

While those C. krusei isolates tested resistant to FCY, AMB and/or one of the azoles revealed susceptibility to all echinocandins, respective C. parapsilosis isolates varied in the echinocandin susceptibility (Table 7). Except
Table 7: Proportion of still susceptible AFAs in relation to AFA-stratified resistances

| Candida species (total number of isolates tested) | Number and percentage (%) of isolates exhibiting S/PAs for | Echinocandins | FIC-Y | AMB-R | FLC-R | VOR-R | POS-R | CAS-R | ANH-R | MCA-R |
|-------------------------------------------------|--------------------------------------------------------|---------------|-------|-------|-------|-------|-------|-------|-------|-------|
| C. albicans (n=557)                              |                                                        | n.a.          | 13 (81.3) | 10 (60.7) | 11 (68.2) | 32 (65.5) | 7 (50.0) | 9 (60.0) | 6 (40.0) | 8 (56.4) |
|                                                |                                                        | n.a.          | 15 (93.8) | 10 (62.5) | 17 (50.0) | 37 (77.1) | 9 (55.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| C. dubliniensis (n=281)                          |                                                        | n.a.          | 2 (100.0) | 1 (50.0) | 1 (50.0) | 1 (23.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (20.0) |
|                                                |                                                        | n.a.          | 2 (100.0) | 1 (50.0) | 1 (50.0) | 1 (23.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (20.0) |
| C. glabrata (n=224)                              |                                                        | n.a.          | 0 (50.0) | 0 (31.8) | 0 (25.0) | 1 (4.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
|                                                |                                                        | n.a.          | 1 (50.0) | 0 (31.8) | 0 (25.0) | 1 (4.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Table 7: Proportion of still susceptible AFAs in relation to AFA-stratified resistances |
|-------------------------------|----------------|-----------------|----------------|----------------|----------------|----------------|
|                               | C. krusei (n=46) |                 |                 |                 |                 |                 |
|                               |                | FCI             | AMB             | Flc             | Vor             | Pos             | CAS             | Mca             | Ant             |
|                               | (n=23)         | (n=15)          | (n=42)          | (n=11)          | (n=22)          | (n=20)          | (n=10)          | (n=8)           | (n=10)          |
| FCY-S                         | n.a.           | 0               | 2.8 (4.8)       | 2 (18.2)        | 2 (8.9)         | 0               | 0               | 0               | 0               |
| AMB-S                         |                | 11 (47.8)       | 28 (66.7)       | 7 (63.6)        | 12 (54.5)       | 0               | 0               | 0               | 0               |
| FLC-S                         |                | 1 (4.3)         | n.a.            | 0               | 0               | 0               | 0               | 0               | 0               |
| Vor-S                         |                | 5 (21.7)        | 1 (13.3)        | 9 (21.4)        | 0               | 0               | 0               | 0               | 0               |
| CAS-S                         |                | 23 (100.0)      | 15 (100.0)      | 42 (100.0)      | 11 (100.0)      | 22 (100.0)      | n.a.            | 0               | 0               |
| MCA-S                         |                | 23 (100.0)      | 15 (100.0)      | 42 (100.0)      | 11 (100.0)      | 22 (100.0)      | 0               | n.a.            | 0               |
| ANI-S                         |                | 23 (100.0)      | 15 (100.0)      | 42 (100.0)      | 11 (100.0)      | 22 (100.0)      | 0               | 0               | n.a.            |
|                               | C. parapsilosis (n=64) |                 |                 |                 |                 |                 |                 |                 |                 |
|                               |                | FCI             | AMB             | Flc             | Vor             | Pos             | CAS             | Mca             | Ant             |
|                               | (n=5)          | (n=12)          | (n=3)           | (n=3)           | (n=3)           | (n=2)           | (n=2)           | (n=2)           | (n=16)          |
| FCY-S                         | n.a.           | 10 (83.3)       | 0               | 1 (33.3)        | 1 (33.3)        | 2 (100.0)       | 2 (100.0)       | 15 (93.8)       |
| AMB-S                         |                | 3 (60.0)        | n.a.            | 2 (66.7)        | 2 (66.7)        | 1 (33.3)        | 1 (50.0)        | 0               | 10 (62.5)       |
| FLC-S                         |                | 0               | 7 (58.3)        | n.a.            | 1 (33.3)        | 0               | 1 (50.0)        | 2 (100.0)       | 9 (56.3)        |
| Vor-S                         |                | 3 (60.0)        | 11 (91.7)       | 1 (33.3)        | n.a.            | 1 (33.3)        | 2 (100.0)       | 2 (100.0)       | 15 (93.8)       |
| CAS-S                         |                | 3 (60.0)        | 9 (75.0)        | 1 (33.3)        | 0               | n.a.            | 2 (100.0)       | 2 (100.0)       | 13 (81.3)       |
| MCA-S                         |                | 5 (100.0)       | 10 (83.3)       | 3 (100.0)       | 3 (100.0)       | 3 (100.0)       | 2 (100.0)       | n.a.            | 14 (87.5)       |
| ANI-S                         |                | 4 (80.0)        | 6 (50.0)        | 2 (66.7)        | 2 (66.7)        | 1 (33.3)        | 1 (50.0)        | 0               | n.a.            |
|                               | C. tropicalis (n=61) |                 |                 |                 |                 |                 |                 |                 |                 |
|                               |                | FCI             | AMB             | Flc             | Vor             | Pos             | CAS             | Mca             | Ant             |
|                               | (n=36)         | (n=10)          | (n=14)          | (n=11)          | (n=14)          | (n=11)          | (n=10)          | (n=8)           | (n=10)          |
| FCY-S                         | n.a.           | 3 (30.0)        | 3 (21.4)        | 4 (36.4)        | 4 (28.6)        | 0               | 0               | 0               | 0               |
| AMB-S                         |                | 29 (80.6)       | 12 (85.7)       | 8 (72.7)        | 10 (71.4)       | 0               | 0               | 1 (100.0)       | 0               |
| FLC-S                         |                | 19 (52.8)       | 8 (80.0)        | n.a.            | 1 (9.1)         | 3 (21.4)        | 1 (100.0)       | 0               | 0               |
| Vor-S                         |                | 27 (75.0)       | 7 (70.0)        | 2 (14.3)        | n.a.            | 4 (28.6)        | 1 (100.0)       | 0               | 0               |
| POS-S                         |                | 18 (50.0)       | 4 (40.0)        | 3 (21.4)        | 1 (9.1)         | n.a.            | 1 (100.0)       | 0               | 0               |
| CAS-S                         |                | 35 (97.2)       | 9 (90.0)        | 14 (100.0)      | 11 (100.0)      | 14 (100.0)      | n.a.            | 0               | 1 (100.0)       |
| MCA-S                         |                | 36 (100.0)      | 10 (100.0)      | 14 (100.0)      | 11 (100.0)      | 14 (100.0)      | 1 (100.0)       | n.a.            | 1 (100.0)       |
| ANI-S                         |                | 35 (97.2)       | 10 (100.0)      | 13 (92.9)       | 10 (90.9)       | 13 (92.9)       | 1 (100.0)       | 0               | n.a.            |

S: susceptible, R: resistant, n.a.: not applicable.
Discussion

In addition to antibiotic resistance towards bacterial and other pathogens, nowadays, also resistance to AFAs has emerged as one of the international health challenges to be addressed. AFA-resistant phenotypes may develop in yeast populations due to mutations, selection processes and alternative mechanisms (e.g. biofilm formation) and a priori-resistant species and strains exist [24]. Moreover, recombination may play also a role in fungi [25]. The fundamental “answer” of the fungal pathogens to the selection pressure by an increasing use of AFAs, however, is represented by shifts in the species and strain distribution towards those species characterized by intrinsic resistances or increased capabilities to express resistance mechanisms [25]. While a shift toward infections caused by non-albicans Candida species have been globally reported [26], [27], [28], a systematic review by Falagas et al. covering the period between 1996 and 2009, showed significant geographic, study design and setting variations of the relative frequency of Candida spp. among cases of candidemia in different parts of the world, consequently, local epidemiological data continue to be of major significance [29].

Here, eight AFAs were tested in parallel, at the same time, in same assay, with the same inocula, thus, all assay-specific parameters were equal for all AFAs allowing a unique, highly standardized evaluation of the isolates’ susceptibilities. Considering pharmacological and pharmacodynamic aspects by a clinical breakpoint based categorisation (S-I-R), the results were arranged to individual SPs reflecting a “fingerprint” for each single isolate, but embedded in the analysis of a large, recent multicentre isolate collection. Defining a fixed AFA sequence for SPA, SPs of different isolates can be easily compared and the frequencies of different SPs are determinable. Depending on the number of AFAs tested in parallel and the amount of parameters compared (e.g. methods, endpoint determinations, breakpoints, MIC categorizations), a multitude of different SPs may have gained allowing detailed analyses of susceptibility distributions, for example, dependent on the methodical approaches used.

While standard descriptive methods and resulting data are the essential basis for questioning resistance preferentially for epidemiologically aspects, clinically and therapeutically relevant problems require comparative susceptibility evaluation methods. For this purpose, comparative AFA evaluation of individual isolate-specific susceptibilities may be useful, e.g. for determination of the prevalence of multi-resistant pathogens or to discover the susceptibility loss to complete AFA classes (e.g. azoles and echinocandins). For that purpose, SPA may act as a useful tool allowing analyses of large strain collections down to the level of individual isolate-specific conclusions [30]. The data gained in this study by analyses of cross-susceptibility and -resistance patterns, respectively, are in particular relevant for treatment-related decisions. Here, of utmost clinical interest are those isolates exhibiting a complete parallel resistance to the entire azole class, in particular, if this is accompanied by a partial or, even worse, a complete echinocandin parallel resistance (Table 5 and Table 6). In contrast to earlier presumptions that no complete echinocandin cross-resistance exists or that there would be only a low potential for the resistance development to echinocandins [8], [31], we could clearly demonstrate by SPA approach that complete parallel resistance within all echinocandins occurs, here found in 1.7% of the clinical routine isolates included. In comparison, the amount of complete parallel resistance within the azole class was 8.8% characterized by species-specific variations.

Although it is reported that clinical isolates with high echinocandin MICs tend to be low [32], isolates with echinocandin MICs of ≥4 mg/L were noted from 17 centres of this study comprising 88 isolates exhibiting those increased MICs for CAS (n=59; 5.6%), ANI (n=55; 5.2%) and MCA (n=26; 2.5%). Increased echinocandin MICs towards one, two and three AFAs of this class were displayed by 54/88 (61.4%), 16/88 (18.1%) and 18/88 (20.5%) of the isolates, respectively.

Complete echinocandin parallel resistance has been noted following prolonged use of these compounds for treatment of C. albicans and C. parapsilosis infections [33], [34]. Here, simultaneous presence of echinocandin- and species-dependent cross-resistance with azoles was found up to 30% depending on candidal species (Table 3 and Table 4).

Selection pressure due to continuous exposure appears to play a crucial role in the emergence of azole resistance, thus, high parallel resistance rates for the azoles have to be noted as shown also in this study (8.8% of all isolates). This pattern is aggravated by cross-resistances of azole-resistant isolates to other AFA groups. In previous studies, none of 315 FLC-resistant Candida isolates demonstrated cross-resistance to ANI, whereas cross-resistance to CAS was rarely found (n=4; 1.1%) [35], [36]. In contrast, elevated cross-resistance frequencies of FLC-resistant yeast isolates (n=173) were found in this study for two echinocandins, ANI (n=18; 10.4%) and CAS (n=17; 9.8%). Cross-resistance between azoles and echinocandins, i.e. multi-resistance with different substance classes, may be caused by common resistance mechanisms such as over-expression of genes encoding efflux pumps, multi-drug transport systems, lipid-associated membrane (protein) functions and/or membrane fluidity [1], [37], [38], [39].

Complete azole-resistant yeast isolates of this study showed cross-resistance to AMB (n=23; 2.2%) and FCY (n=18; 1.7%). In contrast, cross-resistance of the echinocandin-resistant isolates to AMB (n=4; 0.4%) and FCY (n=1; 0.1%) was much rarer. As determined by SPA, a...
The antifungal agents anidulafungin, fluconazole and voriconazole were provided free of charge by Pfizer GmbH (Germany) as were caspofungin by MSD (Germany), posaconazole by Essex (Germany) and miconazole by Astellas Pharma GmbH (Germany). This work was supported by a grant from Pfizer GmbH (Germany) for purchase and manufacturing of culture media, ready-to-use microdilution trays with the antifungal agents and transport material for collected strains. The opinions expressed in this article are those of the authors and do not necessarily represent those of the pharmaceutical companies.

Conflict of interest

K.B. has received research support from Pfizer as well as lecture, travel and other fees from Cubist Pharmaceuticals, MSD Sharp & Dohme, Novartis Pharma and Pfizer. Ch.F. has received lecture, travel and other fees from Pfizer. B.W. has received research support from Pfizer as well as lecture, travel and other fees from Astellas Pharma GmbH, MSD Sharp & Dohme, and Pfizer. All other authors have no conflicts of interest to declare.

Notes

Acknowledgements

The authors would like to thank all members of the Antifungal Susceptibility Testing (AFST) Study Group involved in the German/Austrian multicenter study: F. Albert and C. Schoerner (Universitätsklinikum Erlangen, Institut für Klinische Mikrobiologie, Immunologie und Hygiene); O. Bader and M. Weig (Institut für Medizinische Mikrobiologie, Universitätsklinikum Göttingen); S. Crusius and A. Podbielski (Institut für Medizinische Mikrobiologie und Hygiene, Universität Rostock); V. Czaika (Dept. of Dermatology, Internal Medicine, Helios Kliniken, Bad Saarow); A. Haas (Institut für Medizinische Mikrobiologie der Ludwig-Maximilians-Universität München); G. Haase (Institut für Medizinische Mikrobiologie, RWTH Universität, Aachen); M. Klotz and M. Herrmann (Institut für Mikrobiologie, Universitätsklinikum des Saarlandes, Homburg/Saar); K. Hochauf (Institut für Medizinische Mikrobiologie und Hygiene, Medizinische Fakultät, Technische Universität Dresden); H. Hof (Institut für Medizinische Mikrobiologie und Hygiene, Universitätsklinikum Hannover); A. Rodloff (Institut für Medizinische Mikrobiologie und Infektionsepidermiologie, Universität Leipzig); M. Ruhnke (Medizinische Klinik und Poliklinik II, Onkologie und Hämatologie, Campus Charité Mitte, Humboldt-Universität, Berlin); U. Schumacher (Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Universität Tübingen); L. Sedlacek and S. Suerbaum (Institut für Mikrobiologie und Krankenhaushygiene, Medizinische Hochschule Hannover); I. Sobottka (Institut für Medizinische Mikrobiologie, Virologie und Hygiene, Universitätsklinikum Hamburg-Eppendorf); G. Valenca and M. Abele-Horn (Institut für Hygiene und Mikrobiologie der Universität Würzburg).

The antifungal agents anidulafungin, fluconazole and voriconazole were provided free of charge by Pfizer GmbH.
21. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M, Diekema DJ. Caspofungin activity against clinical isolates of Candida albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010 Nov;14(11):e954-66. DOI: 10.1016/j.ijid.2010.04.006

22. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Jones RN, Turnidge J, Diekema DJ. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol. 2010 Jan;48(1):52-6. DOI: 10.1128/JCM.01590-09

23. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Third Informational Supplement. M27-S3. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.

24. Sanglard D. Resistance of human fungal pathogens to antifungal drugs. Curr Opin Microbiol. 2002 Aug;5(4):379-85. DOI: 10.1016/S1369-5274(02)00344-2

25. Lott TJ, Fraje JP, Lockhart SR. Multilocus sequence type analysis reveals both clonality and recombination in populations of Candida glabrata bloodstream isolates from U.S. surveillance studies. Eurycaryotic Cell. 2010 Apr;9(4):619-25. DOI: 10.1128/EC.00002-10

26. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med. 2006 Mar;34(3):857-63. DOI: 10.1097/01.CCM.0000201897.78123.44

27. Bassetti M, Riggi E, Costa A, Fasce R, Molinari MP, Rosso R, Pallavicini FB, Viscoli C. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21. DOI: 10.1186/1471-2334-6-21

28. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001;7 Suppl 2:8-24. DOI: 10.1111/j.1469-0691.2001.tb00005.x

29. Faïagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010 Nov;14(11):e954-66. DOI: 10.1016/j.ijid.2010.04.006

30. Schmaileck AF, Hof H, Becker K, Fegeler W, Czaika V. Susceptibility patterns and cross-resistance of: antimicrobial peptides (defensins, bacteriocins, ionophores), aminoglycosides, macrolides, penicillins, cephalosporins, and carbapenems in Listeria spp. World Res J Antimicrob Agents. 2014;3(1):39-61.

31. Hof H. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine? Drug Resist Updat. 2008 Feb-Apr;11(1-2):25-31. DOI: 10.1016/j.drup.2008.01.001

32. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother. 2003 Mar;47(3):1068-71. DOI: 10.1128/AAC.47.3.1068-1071.2003

33. Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother. 2006 Apr;57(4):705-8. DOI: 10.1093/jac/dkl022

34. Moudgil V, Little T, Boikov D, Vazquez JA. Multiechinocandin-and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother. 2005 Feb;49(2):767-9. DOI: 10.1128/AAC.49.2.767-769.2005

35. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of amidifungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol. 2005 Nov;43(11):5425-7. DOI: 10.1128/JCM.43.11.5425-5427.2005

36. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol. 2003 Dec;41(12):5729-31. DOI: 10.1128/JCM.41.12.5729-5731.2003
37. Niimi K, Maki K, Ikeda F, Holmes AR, Lamping E, Niimi M, Monk BC, Cannon RD. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob Agents Chemother. 2006 Apr;50(4):1148-55. DOI: 10.1128/AAC.50.4.1148-1155.2006

38. Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, Kuchler K. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol. 2003 Apr;48(1):225-35. DOI: 10.1046/j.1365-2958.2003.03430.x

39. Paderu P, Park S, Perlin DS. Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob Agents Chemother. 2004 Oct;48(10):3845-9. DOI: 10.1128/AAC.48.10.3845-3849.2004

Please cite as
Schmalreck AF, Willinger B, Idelevich EA, Fegeler C, Lass-Flörl C, Fegeler W, Becker K. Parallel and cross-resistances of clinical yeast isolates determined by susceptibility pattern analysis. GMS Infect Dis. 2016;4:Doc02.
DOI: 10.3205/id000020, URN: urn:nbn:de:0183-id0000200

This article is freely available from
http://www.egms.de/en/journals/id/2016-4/id000020.shtml

Published: 2016-06-07

Copyright
©2016 Schmalreck et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Corresponding author:
Karsten Becker
Institute of Medical Microbiology, University Hospital
Münster, Domagkstr. 10, 48149 Münster
kbecker@uni-muenster.de